MA-DESKTOP-METAL
11.7.2022 15:27:07 CEST | Business Wire | Press release
Desktop Metal (NYSE: DM), a global leader in additive manufacturing technologies for mass production, today announced it has expanded its relationship with CNC software innovator SolidCAM, creator of the breakthrough iMachining® toolpath technology and a leading distributor of solutions to precision metal manufacturers worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220711005464/en/
SolidCAM, which was founded in 1984, has offered Desktop Metal products in Germany since 2021. Now, it will offer Desktop Metal solutions for direct printing of metal to customers in the United States, where SolidCAM has technology centers at its US headquarters in Newton, Pa., and Rancho Cucamonga, CA, as well as the United Kingdom, Israel and India. In all, SolidCAM has about 100 direct sales team members worldwide.
Additionally, new CNC + AM Center of Excellence showrooms are currently being completed in Pennsylvania, Germany, and the UK to demonstrate how Desktop Metal’s AM 2.0 solutions complement traditional subtractive machining technology and workflows. Additional facilities are also slated for completion in California, Israel and India.
“The Desktop Metal team is delighted to announce an expansion of our relationship with SolidCAM, a brand that is long trusted by machinists worldwide,” said Ric Fulop, Founder and CEO of Desktop Metal. “This expanded partnership means that more CNC professionals will learn how easy it is to 3D print and sinter complex designs on our Studio System and Shop System metal AM offerings, freeing up capacity on CNC equipment, as well as machinist’s time. Additive manufacturing technology is truly complementary to machining, and we’re eager to deliver that message to the market in partnership with SolidCAM.”
“Our Schramberg Technology Center has already added a Desktop Metal Studio System to its current CNC machines, and we’re in the process of adding more Studio System and Shop System printers to our facilities worldwide so we can demonstrate how this additive manufacturing technology is complementary to CNC machining equipment,” said Dr. Emil Somekh, Founder and CEO of SolidCAM. “The growing impact of additive manufacturing has been well documented. During the COVID-19 epidemic, 3D printing played a critical role in repairing vulnerabilities in supply chains, especially in the medical sector, and we think it can help improve the throughput of supply chains that remain challenged today.”
SolidCAM will be showcasing Desktop Metal equipment and solutions in its booth at IMTS 2022 from Sept. 12 - 17 in Chicago in Booth No. 134502. Desktop Metal will also have two booths at the show, No. 433103 and 432212, where it will be showcasing its metal, polymer, and digital metal casting Additive Manufacturing 2.0 solutions. The International Manufacturing Technology Show, produced by the Association For Manufacturing Technology, is the largest and longest-running industry trade show in the Western Hemisphere.
About Desktop Metal
Desktop Metal, Inc., based in Burlington, Massachusetts, is accelerating the transformation of manufacturing with an expansive portfolio of 3D printing solutions, from rapid prototyping to mass production. Founded in 2015 by leaders in advanced manufacturing, metallurgy, and robotics, the company is addressing the unmet challenges of speed, cost, and quality to make additive manufacturing an essential tool for engineers and manufacturers around the world. Desktop Metal was selected as one of the world’s 30 most promising Technology Pioneers by the World Economic Forum, named to MIT Technology Review’s list of 50 Smartest Companies, and the 2021 winner of Fast Company’s Innovation by Design Award in materials and Fast Company’s Next Big Things in Tech Award for sustainability.
About SolidCAM
SolidCAM is recognized as the world leader in seamless integration of CAM in leading CAD products, SolidWorks and Inventor, supporting the complete range of CNC manufacturing applications, including iMachining 2D/3D, 2.5D milling, high-speed surface milling, 3D high-speed machining, multi-sided indexial 4/5 axes milling, simultaneous 5 axes milling, multi-channel mill-turn, Swiss-type machining and probing. SolidCAM has been a consistent growth leader in CAM. Along with its worldwide branches and affiliates direct sales channels, SolidCAM has a worldwide CAM reseller network, in over 50 countries. The SolidCAM industrial user base includes today more than 24,000 seats.
Forward-looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to, the risks and uncertainties set forth in Desktop Metal, Inc.'s filings with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Desktop Metal, Inc. assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005464/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom